Zoomd Utilized Sciences. Buy, Promote Or Preserve?

ATB Capital Markets analyst Martin Toner maintained an “Outperform” rating and $4.00 purpose on Zoomd Utilized sciences (Zoomd Utilized sciences Stock Quote, Chart, Info, Analysts, Financials TSX:ZOMD) on Nov. 28 following third-quarter outcomes that delivered a revenue miss nevertheless secure profitability.

Toner well-known that Zoomd reported Q3/25 revenue of $16.1-million, down 9% sequentially and below ATB’s $17.9-million estimate, with the shortfall tied to a difficult comparability in direction of a one-time Euro Cup uplift in Q3/24 fairly than a deterioration in underlying demand. Earnings was nonetheless up 7% yr over yr.

Gross income rose to $6.9-million, whereas gross margin expanded 328 basis components yr over yr to 42.6%, though down barely from Q2. Adjusted EBITDA of $4.0-million exceeded ATB’s $3.8-million forecast and was up 2% yr over yr nevertheless down 29% from Q2. EPS of $0.06 missed ATB’s $0.07 estimate.

Administration talked about it’s shifting in direction of “higher-quality revenue” and specializing in geographic development in North America and Europe. Toner well-known Zoomd added better than ten new purchasers all through iGaming, fintech and e-commerce. He talked about the E2 partnership strengthens publicity to sports activities actions and betting purchasers and can help higher-margin revenue.

Toner emphasised that adtech revenue could also be uneven for smaller players nevertheless talked about he stays assured in Zoomd’s talent in order so as to add prospects and improve inside its present base. He talked about the company’s margin profile, cash conversion and capital self-discipline keep key positives as a result of the enterprise undergoes “vital modifications.”

ATB’s forecasts and purpose are unchanged pending additional component on the outlook from administration’s conference identify.

-30-